Daewoong Pharmaceutical's new diabetes drug, Enblo, is gaining significant attention following findings that it can improve fatty liver conditions in patients with type 2 diabetes. Enblo is showing potential not only for blood sugar control but also as a treatment that can manage fatty liver, a common comorbidity of diabetes, raising hopes for its future development.

Research Findings on Enblo

Daewoong Pharmaceutical has published research results on Enblo, a new SGLT-2 inhibitor diabetes drug, demonstrating its potential to improve liver steatosis. This study was published in the international journal "Diabetes, Obesity and Metabolism." SGLT-2 inhibitors are known as type 2 diabetes treatments that block glucose reabsorption in the kidneys, leading to its excretion in urine.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Enblo

This study evaluated the improvement effects of Enblo on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition frequently accompanying diabetes. MASLD is characterized by excessive fat accumulation in the liver due to metabolic dysfunction and can lead to liver and cardiovascular diseases if left untreated. With the increasing prevalence of MASLD among type 2 diabetes patients, the need for treatments that address not only blood sugar control but also liver metabolic improvement is becoming more critical.

Analysis of Clinical Trial Results

To support Enblo's market approval, researchers conducted an integrated analysis of clinical trial data from 587 type 2 diabetes patients over a 24-week treatment period. Fatty liver levels were measured using the Hepatic Steatosis Index (HSI) and the Framingham Steatosis Index (FSI). At the start of the study, approximately half of all patients had accompanying fatty liver. The proportion of patients whose fatty liver levels decreased was notably higher in the Enblo treatment group.

• According to the HSI assessment, the number of fatty liver patients in the Enblo group decreased from 36 (48.0%) to 12 (16.0%), indicating an improvement to normal range for approximately 67% of patients.
• Based on the FSI, the number of patients at risk decreased from 31 (41.3%) to 12 (16.0%), showing an improvement to normal range for about 61%.

Significance and Expectations for Enblo

This study is considered significant as it is the first to confirm Enblo's ability to improve fatty liver indicators in type 2 diabetes patients. Notably, when compared to dapagliflozin, another drug in the same class, the Enblo treatment group showed a greater improvement in fatty liver levels. The corresponding author of the study stated, "We have confirmed that Enblo has the potential to positively impact not only blood sugar control but also reduce fat accumulation in the liver."

Park Hyung-cheol, head of Daewoong Pharmaceutical's ETC Marketing Division, commented, "These research results demonstrate that Enblo can offer additional therapeutic benefits beyond blood sugar control, including the improvement of fatty liver indicators." Given that MASLD has a high comorbidity rate of over 65% in type 2 diabetes patients, the therapeutic value of Enblo is highly anticipated.